Skip to main content
editor@theusajournals.com | Oscar Publishing Services Journal Home
Login

American Journal Of Biomedical Science & Pharmaceutical Innovation

Peer Reviewed | Open Access | E-ISSN: 2771-2753
Published Article

Modern Methods of Diagnosis and Treatment of Systemic Lupus Erythematosus

Modern Methods of Diagnosis and Treatment of Systemic Lupus Erythematosus

Authors

  • Azimova Mavlyuda Makhmudovna
    PhD, Associate Professor of department “Propaedeutics of Internal Diseases No. 2”, Tashkent State Medical University, Tashkent, Uzbekistan
  • Irisbekov Behruz
    3nd-year student, Faculty of General Medicine, Group 302B, Tashkent State Medical University, Tashkent, Uzbekistan

DOI:

https://doi.org/10.37547/ajbspi/Volume06Issue02-09

Keywords:

Systemic lupus erythematosus autoimmune disease antinuclear antibodies

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune connective tissue disorder with multiorgan involvement, characterized by impaired immunologic tolerance, B-cell hyperactivation, and activation of the interferon cascade. Contemporary diagnostic approaches include expanded immunologic profiling, molecular genetic studies, and the use of biomarkers of organ damage. SLE treatment is currently shifting from nonspecific immunosuppression toward personalized targeted therapy. The introduction of biologic agents and the treat-to-target strategy has substantially improved disease prognosis.

References

Aringer M., Costenbader K., Daikh D., et al.

European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Annals of the Rheumatic Diseases. 2019;78(9):1151–1159.

doi:10.1136/annrheumdis-2018-214819

Fanouriakis A., Kostopoulou M., Alunno A., et al.

update of the EULAR recommendations for the management of systemic lupus erythematosus.

Annals of the Rheumatic Diseases. 2019;78:736–745.

doi:10.1136/annrheumdis-2019-215089

Fanouriakis A., et al.

update of the EULAR recommendations for the management of systemic lupus erythematosus.

Annals of the Rheumatic Diseases. 2023.

Rovin B.H., Adler S.G., Barratt J., et al.

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.

Kidney International. 2021;100(4S):S1–S276.

Navarra S.V., Guzmán R.M., Gallacher A.E., et al.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

The Lancet. 2011;377:721–731.

Furie R., Morand E.F., Askanase A.D., et al.

Trial of Anifrolumab in Active Systemic Lupus Erythematosus.

New England Journal of Medicine. 2020;382:211–221.

Tsokos G.C.

Systemic lupus erythematosus.

New England Journal of Medicine. 2011;365:2110–2121.

Rahman A., Isenberg D.A.

Systemic lupus erythematosus.

The Lancet. 2008;371:1205–1217.

Kaul A., Gordon C., Crow M.K., et al.

Systemic lupus erythematosus.

Nature Reviews Disease Primers. 2016;2:16039.

Yen E.Y., Singh R.R.

Lupus — an unrecognized leading cause of death in young females: a population-based study.

Arthritis & Rheumatology. 2017;69(8):1612–1618.

Durcan L., O’Dwyer T., Petri M.

Management strategies and future directions for systemic lupus erythematosus in adults.

The Lancet. 2019;393:2332–2343.